pirinixic acid has been researched along with Dyslipidemia in 4 studies
pirinixic acid: structure
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 7.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| "05) by treatment with 300 mg fenofibrate once daily for 4 weeks in 13 patients with dyslipidemia." | 3.77 | Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets. ( Abe, M; Aihara, K; Akaike, M; Azuma, H; Hashizume, S; Ikeda, Y; Ishikawa, K; Iwase, T; Matsumoto, T; Sata, M; Sumitomo-Ueda, Y; Yagi, S; Yoshida, S, 2011) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 3.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashizume, S | 1 |
| Akaike, M | 1 |
| Azuma, H | 1 |
| Ishikawa, K | 1 |
| Yoshida, S | 1 |
| Sumitomo-Ueda, Y | 1 |
| Yagi, S | 1 |
| Ikeda, Y | 1 |
| Iwase, T | 1 |
| Aihara, K | 1 |
| Abe, M | 1 |
| Sata, M | 1 |
| Matsumoto, T | 1 |
| Li, PP | 1 |
| Shan, S | 1 |
| Chen, YT | 1 |
| Ning, ZQ | 1 |
| Sun, SJ | 1 |
| Liu, Q | 1 |
| Lu, XP | 1 |
| Xie, MZ | 1 |
| Shen, ZF | 1 |
| Lanne, B | 2 |
| Dahllöf, B | 1 |
| Lindahl, C | 1 |
| Ebefors, K | 1 |
| Kanmert, I | 1 |
| von Bahr, H | 1 |
| Miliotis, T | 1 |
| Nyström, AC | 1 |
| Arnerup, G | 1 |
| Paulsons, I | 1 |
| Kerb, S | 1 |
| Oakes, N | 1 |
| Sheikh, K | 1 |
| Camejo, G | 1 |
| Halvarsson, T | 1 |
| Landergren, MR | 1 |
| Oakes, ND | 1 |
4 other studies available for pirinixic acid and Dyslipidemia
| Article | Year |
|---|---|
Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets.
Topics: Adult; Becaplermin; Blood Platelets; Cell Differentiation; Cell Line, Tumor; Dyslipidemias; Female; | 2011 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expr | 2006 |
PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents.
Topics: Adipose Tissue; Animals; Dyslipidemias; Hypoglycemic Agents; Liver; Male; Mice; Mice, Obese; Peroxis | 2006 |
Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat.
Topics: Amino Acids; Animal Feed; Animals; Chromatography, High Pressure Liquid; Dietary Fats; Dyslipidemias | 2007 |